{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:52:49Z","timestamp":1783655569811,"version":"3.55.0"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cenobamate (CNB) and lacosamide (LCM) are two common used third-generation anti-seizure medications (ASMs) for third-line treatment of the drug-resistant epilepsy. The real-world data on adverse events (AEs) related to them remains limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All data obtained from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, covering the period from 2008 to 2024. The reporting odds ratio, proportional reporting ratio and bayesian confidence propagation neural network to assess and compare the safety signals of CNB and LCM for comparison.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 50,323,324 AE reports were recorded, with 3,584 for CNB and 13,874 for LCM. The most significant signals were primarily in nervous system and psychiatric disorders, resembling those of traditional sodium channel blockers. Unreported AEs in the drug dispensatory were identified in LCM (multiple-drug resistance). Notable differences between LCM and CNB emerged: Certain numbers of AE signals associated with LCM were found in cardiac disorders, while no such relevant signals were detected for CNB; among the signals that detected in both drugs, most signals from CNB are stronger than those from LCM; The initial titration dose of CNB (12.5\u202fmg, qd) reported a significantly higher number of AEs compared to the other dose groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Choosing the right ASMs requires consideration of the type of epilepsy, the individual tolerance and potential severe toxicity of different medications. Although the disproportionality analysis is a hypothesis generating, we provide a reference for the clinical safety of CNB and LCM.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1625612","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:08:00Z","timestamp":1756825680000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world safety comparison between cenobamate and lacosamide: a pharmacovigilance study based on the FDA Adverse Event Reporting System"],"prefix":"10.3389","volume":"16","author":[{"given":"Shenglan","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengrui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyue","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000503831","article-title":"The epidemiology of epilepsy","volume":"54","author":"Beghi","year":"2020","journal-title":"Neuroepidemiology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1528-1167.2012.03416.x","article-title":"Focal epilepsies in adult patients attending two epilepsy centers: classification of drug-resistance, assessment of risk factors, and usefulness of \u201cnew\u201d antiepileptic drugs","volume":"53","author":"Gilioli","year":"2012","journal-title":"Epilepsia"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/epi4.12967","article-title":"Real-world anti-seizure treatment and adverse events among individuals living with drug-resistant focal epilepsy in the United States","volume":"9","author":"Mao","year":"2024","journal-title":"Epilepsia Open."},{"key":"ref5","year":""},{"key":"ref6","year":""},{"key":"ref7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.seizure.2023.07.026","article-title":"Cenobamate in patients with highly refractory focal epilepsy: a retrospective real-world study","volume":"111","author":"Beltr\u00e1n-Corbellini","year":"2023","journal-title":"Seizure"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2023.09.006","article-title":"Real-world experience with cenobamate: a systematic review and meta-analysis","volume":"112","author":"Makridis","year":"2023","journal-title":"Seizure"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","article-title":"Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons","volume":"855","author":"Nakamura","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"173117","DOI":"10.1016\/j.ejphar.2020.173117","article-title":"Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate","volume":"879","author":"Sharma","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","article-title":"Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability","volume":"35","author":"Roberti","year":"2021","journal-title":"CNS Drugs"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.seizure.2023.02.015","article-title":"Increasing use of newer antiseizure medication during pregnancy: an observational study with special focus on lacosamide","volume":"107","author":"Hoeltzenbein","year":"2023","journal-title":"Seizure"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","article-title":"Current understanding of the mechanism of action of the antiepileptic drug lacosamide","volume":"110","author":"Rogawski","year":"2015","journal-title":"Epilepsy Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s12035-014-8775-9","article-title":"Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide","volume":"51","author":"Wilson","year":"2015","journal-title":"Mol Neurobiol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/14740338.2020.1713089","article-title":"The adverse-effect profile of lacosamide","volume":"19","author":"Li","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yebeh.2015.09.006","article-title":"Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials","volume":"52","author":"Biton","year":"2015","journal-title":"Epilepsy Behav"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/17562864241256733","article-title":"Therapeutic strategies during cenobamate treatment initiation: Delphi panel recommendations","volume":"17","author":"Steinhoff","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/2168479013514236","article-title":"A review of statistical methods for safety surveillance","volume":"48","author":"Huang","year":"2014","journal-title":"Ther Innov Regul Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/epi4.12992","article-title":"The cenobamate KORK study-A prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add-on lacosamide, perampanel, and brivaracetam","volume":"9","author":"Steinhoff","year":"2024","journal-title":"Epilepsia Open"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"109605","DOI":"10.1016\/j.yebeh.2023.109605","article-title":"Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies","volume":"151","author":"Krauss","year":"2024","journal-title":"Epilepsy Behav"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.1007\/s00415-024-12510-1","article-title":"Cenobamate: real-world data from a retrospective multicenter study","volume":"271","author":"Lauxmann","year":"2024","journal-title":"J Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1111\/epi.17091","article-title":"Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study","volume":"62","author":"Sperling","year":"2021","journal-title":"Epilepsia"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1111\/epi.17092","article-title":"Dose adjustments to concomitant antiseizure medications: post-hoc analysis of a phase 3, open-label study of cenobamate for treatment of unco2021ntrolled focal seizure","volume":"62","author":"Rosenfeld","year":"2021","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1080\/00207454.2017.1408619","article-title":"Influence of adjunctive lacosamide in patients with seizures: a systematic review and meta-analysis","volume":"128","author":"Liu","year":"2018","journal-title":"Int J Neurosci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/ane.12920","article-title":"Lacosamide monotherapy in clinical practice: a retrospective chart review","volume":"138","author":"Villanueva","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/acn3.52004","article-title":"Efficacy and tolerability of adjunctive lacosamide in patients aged <4\u202fyears with focal seizures","volume":"11","author":"Makedonska","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.seizure.2015.07.001","article-title":"Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: a multicentre open-label trial","volume":"31","author":"Zadeh","year":"2015","journal-title":"Seizure"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","article-title":"Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy","volume":"76","author":"Chen","year":"2017","journal-title":"Epilepsy Behav"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.eplepsyres.2016.08.032","article-title":"Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: A randomized, double-blind, placebo-controlled study","volume":"127","author":"Hong","year":"2016","journal-title":"Epilepsy Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"107580","DOI":"10.1016\/j.yebeh.2020.107580","article-title":"The effects of lacosamide on cognitive function and psychiatric profiles in patients with epilepsy","volume":"113","author":"Li","year":"2020","journal-title":"Epilepsy Behav"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"32118","DOI":"10.1073\/pnas.2100032118","article-title":"Clinical evidence that a dysregulated master neural network modulator may aid in diagnosing schizophrenia","volume":"118","author":"Nomoto","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1093\/eurheartj\/ehad523","article-title":"Epilepsy and long-term risk of arrhythmias","volume":"44","author":"Wang","year":"2023","journal-title":"Eur Heart J"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2165\/00023210-200923070-00002","article-title":"Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders","volume":"23","author":"Curia","year":"2009","journal-title":"CNS Drugs"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/ane.12414","article-title":"Lacosamide cardiac safety: clinical trials in patients with partial-onset seizures","volume":"132","author":"Rudd","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/ane.12413","article-title":"Cardiac safety of lacosamide: the non-clinical perspective","volume":"132","author":"Delaunois","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1161\/CIR.0000000000000905","article-title":"Drug-induced arrhythmias: a scientific statement from the American Heart Association","volume":"142","author":"Tisdale","year":"2020","journal-title":"Circulation"},{"key":"ref40","year":""},{"key":"ref41","first-page":"641","article-title":"Lacosamide","volume-title":"Treatment of epilepsy","author":"Wechsler","year":"2021"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s12012-018-9467-x","article-title":"Complete atrioventricular block in an elderly patient treated with low-dose lacosamide","volume":"18","author":"Lachuer","year":"2018","journal-title":"Cardiovasc Toxicol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.yebeh.2011.02.006","article-title":"Atrioventricular block following lacosamide intoxication","volume":"20","author":"Krause","year":"2011","journal-title":"Epilepsy Behav"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/0897190017700557","article-title":"Lacosamide-induced recurrent ventricular tachycardia in the acute care setting","volume":"31","author":"Berei","year":"2018","journal-title":"J Pharm Pract"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e20736","DOI":"10.7759\/cureus.20736","article-title":"Lacosamide-related arrhythmias: a systematic analysis and review of the literature","volume":"13","author":"Yadav","year":"2021","journal-title":"Cureus"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12883-021-02253-1","article-title":"Lacosamide-induced sinus node dysfunction followed by severe agranulocytosis","volume":"21","author":"Shibata","year":"2021","journal-title":"BMC Neurol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"16202","DOI":"10.1038\/s41598-024-67209-0","article-title":"Cardiac adverse events associated with lacosamide: a disproportionality analysis of the FAERS database","volume":"14","author":"Yang","year":"2024","journal-title":"Sci Rep"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1111\/epi.13502","article-title":"Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: results from a multicenter, open-label trial","volume":"57","author":"Vossler","year":"2016","journal-title":"Epilepsia"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"106710","DOI":"10.1016\/j.eplepsyres.2021.106710","article-title":"Cardiac effects of rapid intravenous loading of lacosamide in patients with epilepsy","volume":"176","author":"Kim","year":"2021","journal-title":"Epilepsy Res"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"891368","DOI":"10.3389\/fneur.2022.891368","article-title":"Evaluation of cardiovascular concerns of intravenous lacosamide therapy in epilepsy patients","volume":"13","author":"Lu","year":"2022","journal-title":"Front Neurol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e25577","DOI":"10.1097\/MD.0000000000025577","article-title":"Lacosamide induced brugada I morphology in the setting of septicemia: a case report","volume":"100","author":"Goodnough","year":"2021","journal-title":"Medicine"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.pjnns.2017.03.003","article-title":"Lacosamide during pregnancy and breastfeeding","volume":"51","author":"Lattanzi","year":"2017","journal-title":"Neurol Neurochir Pol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1055\/s-0042-1759579","article-title":"Preventing teratogenicity in women with epilepsy","volume":"42","author":"Kinney","year":"2022","journal-title":"Semin Neurol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1111\/epi.17395","article-title":"Lacosamide effects on placental carriers of essential compounds in comparison with valproate: studies in perfused human placentas","volume":"63","author":"Berman","year":"2022","journal-title":"Epilepsia"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e209279","DOI":"10.1212\/WNL.0000000000209279","article-title":"Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to Antiseizure medication: practice guideline from the AAN, AES, and SMFM","volume":"102","author":"Pack","year":"2024","journal-title":"Neurology"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40120-022-00400-5","article-title":"Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations","volume":"11","author":"Smith","year":"2022","journal-title":"Neurol Ther"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"109156","DOI":"10.1016\/j.yebeh.2023.109156","article-title":"The cenobamate-clobazam interaction- evidence of synergy in addition to pharmacokinetic interaction","volume":"142","author":"Osborn","year":"2023","journal-title":"Epilepsy Behav"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1111\/epi.17515","article-title":"A retrospective non-interventional study evaluating the pharmacokinetic interactions between cenobamate and clobazam","volume":"64","author":"Elakkary","year":"2023","journal-title":"Epilepsia"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"107306","DOI":"10.1016\/j.eplepsyres.2024.107306","article-title":"Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study","volume":"200","author":"Aboumatar","year":"2024","journal-title":"Epilepsy Res"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"107242","DOI":"10.1016\/j.eplepsyres.2023.107242","article-title":"Dose reduction and discontinuation of concomitant antiseizure medications after initiating cenobamate: A retrospective review","volume":"197","author":"Becker","year":"2023","journal-title":"Epilepsy Res"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/epi4.12936","article-title":"Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures","volume":"9","author":"Carre\u00f1o","year":"2024","journal-title":"Epilepsia Open"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e200151","DOI":"10.1212\/NXI.0000000000200151","article-title":"Cenobamate and clobazam combination as personalized medicine in autoimmune-associated epilepsy with anti-GAD65 antibodies","volume":"10","author":"Serrano-Castro","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/FPC.0b013e3282f85e36","article-title":"Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs","volume":"18","author":"Hung","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/FTD.0000000000000927","article-title":"Impact of ABCB1 polymorphisms on Lacosamide serum concentrations in Uygur pediatric patients with epilepsy in China","volume":"44","author":"Zhao","year":"2022","journal-title":"Ther Drug Monit"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.seizure.2018.07.011","article-title":"Evaluation of long-term antiepileptic drug use in patients with temporal lobe epilepsy: assessment of risk factors for drug resistance and polypharmacy","volume":"61","author":"Bj\u00f8rke","year":"2018","journal-title":"Seizure"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.3390\/ijms24054848","article-title":"Frontline Sodium Channel-blocking Antiseizure medicine use promotes future onset of drug-resistant chronic seizures","volume":"24","author":"Zierath","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1111\/epi.14454","article-title":"Long-term negative impact of an inappropriate first antiepileptic medication on the efficacy of a second antiepileptic medication in mice","volume":"59","author":"Pawluski","year":"2018","journal-title":"Epilepsia"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/j.1528-1167.2011.03325.x","article-title":"Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments","volume":"52","author":"Luoni","year":"2011","journal-title":"Epilepsia"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/epi.13871","article-title":"Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis","volume":"58","author":"Androsova","year":"2017","journal-title":"Epilepsia"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1625612\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:08:01Z","timestamp":1756825681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1625612\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":71,"alternative-id":["10.3389\/fneur.2025.1625612"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1625612","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"article-number":"1625612"}}